Search

Displaying results 1961 - 1970 of 10000 in total
  1. Drug

    Lyme disease vaccine (recombinant OspA)

    go.drugbank.com/drugs/DB00045
    ApprovedWithdrawn

    Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.

    Synonyms: Lipoprotein outer surface a borrelia burgdorferi antigen
  2. Drug

    Dactinomycin

    go.drugbank.com/drugs/DB00970
    ApprovedInvestigational

    A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. … As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsSynonyms: Actinomycin IV
  3. Drug

    Interferon beta-1b

    go.drugbank.com/drugs/DB00068
    ApprovedInvestigational

    Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  4. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    Tilactase is a beta-D-galactosidase obtained from _Aspergillus oryzae_. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. … [A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain.

  5. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection. … An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.

  6. Drug

    Cyproheptadine

    go.drugbank.com/drugs/DB00434
    ApprovedInvestigational

    Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors.

    Synonyms: 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine, 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
  7. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    Because Hly is only active at an acidic pH, similar to listeriolysin O, the deletion of urease C was also beneficial for Hly to have optimal bioactivity in the phagosome. … VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other

  8. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant … In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months

  9. Drug

    Tinzaparin

    go.drugbank.com/drugs/DB06822
    ApprovedInvestigational

    It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. … It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally.

  10. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Tividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099 … Hunter syndrome is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), which leads to the toxic accumulation of glycosaminoglycans (GAGs) throughout

    Synonyms: 676>S, L 678>A, Y, - L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, T